Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2510 combined with IMM01 in advanced solid tumors
NCT07170787Phase 2Not yet recruiting
- Sponsor
- ImmuneOnco
- Start
- Oct 2025
- Primary completion
- Feb 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IMM2510, timdarpacept in solid tumor (advanced stage), sponsored by ImmuneOnco. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
IMM2510timdarpacept
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07170787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170787.